[Drug treatment of osteoporosis]

Dtsch Med Wochenschr. 2014 Mar;139(10):497-500. doi: 10.1055/s-0033-1360087. Epub 2014 Feb 25.
[Article in German]
No abstract available

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Biphenyl Compounds / adverse effects
  • Biphenyl Compounds / therapeutic use
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use*
  • Calcium, Dietary / administration & dosage
  • Cause of Death
  • Combined Modality Therapy
  • Cross-Sectional Studies
  • Denosumab
  • Diphosphonates / adverse effects
  • Diphosphonates / therapeutic use
  • Female
  • Germany
  • Humans
  • Life Style
  • Male
  • Middle Aged
  • Osteoporosis / drug therapy*
  • Osteoporosis / epidemiology
  • Osteoporosis / mortality
  • Osteoporosis / prevention & control
  • Osteoporotic Fractures / epidemiology
  • Osteoporotic Fractures / mortality
  • Osteoporotic Fractures / prevention & control
  • Population Dynamics
  • Risk Factors
  • Selective Estrogen Receptor Modulators / adverse effects
  • Selective Estrogen Receptor Modulators / therapeutic use
  • Vitamin D / administration & dosage

Substances

  • Antibodies, Monoclonal, Humanized
  • Biphenyl Compounds
  • Bone Density Conservation Agents
  • Calcium, Dietary
  • Diphosphonates
  • Selective Estrogen Receptor Modulators
  • Vitamin D
  • Denosumab
  • odanacatib